JPRN-jRCTs061210081已完成未知
Single-center, randomized, single-blind, parallel-group comparative study of investigating the effects of moisturizers on basal sweating and microcirculation in patients with Asteatosis
Aoyama Yumi0 个研究点目标入组 40 人开始时间: 2022年3月2日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •(1)Patients who have asteatosis, with no sign of eczema lower leg on the day of the treatment start
- •(2)Patients 20 years and older at the time of informed consent
排除标准
- •(1) Patients with any of the following medical histories
- •1) Serious allergies (shock, anaphylaxis-like symptoms)
- •2) Hypersensitivity to heparinoid-containing preparations
- •3) Hypersensitivity to PROPETO (White Petrolatum)
- •4) Skin hypersensitivity to topical medicines (contact dermatitis, etc.)
- •(2) Patients with any of the following diseases
- •1)Serious diseases of the heart, liver, kidneys, lungs, and blood that investigator have considered are inappropriate for participate in study.
- •2)Malignant tumor, except for there is no treatment and no recurrence for the past 5 years or history of curative treatment for the cervical intraepithelial neoplasia at the time of informed consent
- •3) Skin diseases other than the asteatosis that occur at the evaluation area of this study
- •4) Diseases such as hyperhidrosis and microcirculatory disorder symptoms in which the amount of sweating and blood flow are not stable
- •5) Hemorrhagic blood diseases (hemophilia, thrombocytopenia, purpura, etc.)
- •(3) Patient who are expected to become serious even if they bleed slightly
- •(4) Patient enrolled in this study in the past
- •(5) Patient participating in other clinical studies, clinical trials or post-marketing clinical trials
- •(6) Patient who used topical drugs (including over-the-counter drugs, quasi-drugs, and cosmetics) for the rash on the lower leg with asteatosis within 14 days before the start of treatment
- •(7) Patient who took oral antihistamine or oral antiallergic drug within 14 days before the start of treatment
- •(8) Patient who used medicine that change sweating or blood flow within 14 days before the start of treatment (excluding Chinese medicine, including off-label use hyperhidrosis medicine)
- •(9) Patient who took oral corticosteroids within 3 months (90 days) before the start of treatment
- •(10) Female patient, who be pregnant or lactating or may be pregnant
- •(11) COVID-19 patients (including asymptomatic pathogen carriers) or who suspected COVID-19 infection
- •(12) Patient who were found to have close contact with COVID-19 patients (including asymptomatic pathogen carriers) within 14 days prior to the start of treatment
- •(13)patient who is judged by the principal investigator or sub- investigator to be ineligible for this study for any other reason
研究者
相似试验
已完成
不适用
Single-center, randomized, double-blind, single-dose, 3-way crossover study to compare the effects of daridorexant and placebo on postural stability, the auditory awakening threshold, and cognitive function in the middle-of-the-night following evening administration to healthy adult and elderly subjectsInsomniaNL-OMON51304Idorsia Pharmaceuticals Ltd36
已完成
不适用
Single center, double-blind, randomized, parallel trial to evaluate the efficacy of rhizopus koji extract containing food in subjects with menopause symptommenopause symptomJPRN-UMIN000017821SHIKOSHI RESEARCH INSTITUTE FOR PHYSIOLOGY CO.,LTD.20
已完成
不适用
Single center, double-blind, randomized, parallel trial to evaluate the efficacy of food containing yeast on human gastrointestinal functioSlight constipationJPRN-UMIN000020476Prime Biz Corporation50
暂停
Unknown
A clinical trial to evaluate the temporary cognitive function improvement effect and safety of a low-frequency stimulation treatment device for 9 months in patients with Alzheimer's type mild cognitive impairment receiving drug treatment.Mental and behavioural disordersKCT0009136Ecure30
进行中（未招募）
1 期
Multicenter, parallel, randomized, single-blind trial comparing the efficacy and tolerability of Rhinaction®, an osmotic decongestant nasal spray containing essential oils versus Olynth® 0.1%, a vasoconstrictor, in the relief of acute rhinitis symptoms in adults.Acute rhinitisAdults aged =18years old suffering from acute rhinitis with symptoms present for up to 72h. The purpose of this study is to demonstrate the efficacy and compare safety and tolerability of Medical Device class I Rhinaction® as well as its non-inferiority when compared to Medical Product Olynth® 0.1% in cases of acute rhinitis in adults up to 8 days of administrationEUCTR2015-002796-23-CZaboratoire de la Mer